share_log

Truist Securities Reiterates Buy on Adverum Biotechnologies, Maintains $6 Price Target

Benzinga ·  Sep 5, 2023 10:03

Truist Securities analyst Joon Lee reiterates Adverum Biotechnologies (NASDAQ:ADVM) with a Buy and maintains $6 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment